CA Patent

CA2815361A1 — Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers

Assigned to GlycoMark Inc · Expires 2012-04-26 · 14y expired

What this patent protects

Described herein is a method for determining the disease state in a patient using combined mean glucose measurements and 1,5-anhydroglucitoi to identify individuals at risk for developing diabetes. The ratio of mean glucose measurements to 1,5-anhydroglucitol correlates significa…

USPTO Abstract

Described herein is a method for determining the disease state in a patient using combined mean glucose measurements and 1,5-anhydroglucitoi to identify individuals at risk for developing diabetes. The ratio of mean glucose measurements to 1,5-anhydroglucitol correlates significantly better to maximal levels of postmeal glucose levels and related measurements, than mean glucose measurements or 1,5-anhydroglucitol correlate independent!y.

Drugs covered by this patent

Patent Metadata

Patent number
CA2815361A1
Jurisdiction
CA
Classification
—
Expires
2012-04-26
Drug substance claim
No
Drug product claim
No
Assignee
GlycoMark Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.